Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, accelerating Qiagen’s entrance into high‑throughput, instrument‑free single‑cell genomics. The deal expands Qiagen’s sample‑to‑informatics portfolio and aims to pair Parse’s plate‑based, scalable single‑cell prep with Qiagen’s global lab footprint. The company said the move complements planned launches of new sample‑prep instruments and supports pharma and academic customers scaling single‑cell projects. CEO Thierry Bernard will step down as part of leadership changes tied to the transaction.